Evidence map›Paper›PMID 29502297›Full record

ArticleParasitology research2018

Chlorinated metronidazole as a promising alternative for treating trichomoniasis.

M O Chacon, T H S Fonseca, S B V Oliveira, M A Alacoque, L L Franco, C A Tagliati, G D Cassali, G P Campos-Mota, R J Alves, L S A Capettini and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Parasitology research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Discovery of thienopyrimidine analog G-18 as a novel anti-trichomonal agent.International journal for parasitology. Drugs and drug resistance · 2026
    Article
  2. Review
  3. Article
  4. Management of Resistant Trichomoniasis.Current infectious disease reports · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

M O ChaconDepartment of Parasitology, Instituto de Ciências Biológicas (ICB), Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, MG, Brazil.
T H S FonsecaDepartment of Parasitology, Instituto de Ciências Biológicas (ICB), Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, MG, Brazil.
S B V OliveiraDepartment of Parasitology, Instituto de Ciências Biológicas (ICB), Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, MG, Brazil.
M A AlacoqueDepartment of Parasitology, Instituto de Ciências Biológicas (ICB), Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, MG, Brazil.
L L FrancoDepartment of Pharmaceutical Products, Faculdade de Farmárcia, UFMG, Belo Horizonte, MG, Brazil.
C A TagliatiDepartment of Toxicology, Faculdade de Farmárcia, UFMG, Belo Horizonte, MG, Brazil.
G D CassaliDepartment of Pathology, ICB, UFMG, Belo Horizonte, MG, Brazil.
G P Campos-MotaDepartment of Pharmacology, ICB, UFMG, Belo Horizonte, MG, Brazil.
R J AlvesDepartment of Pharmaceutical Products, Faculdade de Farmárcia, UFMG, Belo Horizonte, MG, Brazil.
L S A CapettiniDepartment of Pharmacology, ICB, UFMG, Belo Horizonte, MG, Brazil.
Maria Aparecida GomesDepartment of Parasitology, Instituto de Ciências Biológicas (ICB), Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, MG, Brazil. magomes@icb.ufmg.br.ORCID http://orcid.org/0000-0002-7263-5721

Funding

Conselho Nacional de Desenvolvimento Científico e Tecnológico (BR) 449360-2014-8
6 · The paper itself

Abstract

Trichomoniasis is the most common non-viral, sexually transmitted infection affecting humans worldwide. The main treatment for trichomoniasis is metronidazole (MTZ). However, adverse effects and reports of resistance have stimulated the development of therapeutic alternatives. The ease of manipulation of the side chains of MTZ coupled with its safety makes this molecule attractive for the development of new drugs. In this context, we evaluated the activity of the chlorinated MTZ derivative, MTZ-Cl, on sensitive and resistant strains of Trichomonas vaginalis. MTZ-Cl presented a remarkable activity against both sensitive and resistant strains. In vitro and in vivo toxicity assays indicated that the new molecule is safe for future clinical trials. Furthermore, we noticed different rates of free radical production between the sensitive and resistant strains. MTZ-Cl induced a higher release of nitric oxide (NO, ~ 9000 a.u.) by both sensitive and resistant strains. However, the sensitive strain produced a greater amount of H

Indexed as

AnimalsAntiprotozoal AgentsCell LineHalogenationHumansHydrogen PeroxideMetronidazoleNitric OxideRatsSexually Transmitted DiseasesTrichomonas InfectionsTrichomonas vaginalisAntiprotozoal AgentsHydrogen PeroxideMetronidazoleNitric OxideMetronidazole analogueResistanceTreatmentTrichomonas vaginalis

Identifiers

PMID29502297

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.